Industry observers maintain that capital is available for companies that have the right formula for success
With almost-daily headlines chronicling funding and scientific setbacks to the biotechnology industry, the challenges for scientist- entrepreneurs contemplating making a go of their idea seem daunting, even insurmountable.

Yet biotech analysts, officials, researchers, and other observers insist that, despite the depressed financial climate in the industry and investor wariness, capital should be available in 1995 for startups with the right formula for success. At the core of this mixture, they say, are sound ideas with high product potential, backed by a solid business plan and a management team that combines scientific savvy with entrepreneurial skills.

"The outlook for startups is surprisingly positive_the terms may be difficult when actually making a deal, but there's a lot more [start-up activity] going on than you would think," maintains Kenneth B. Lee, the national director of the life...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?